Vancomycin-resistant Staphylococcus aureus




















Vancomycin-resistant Staphylococcus aureus
Staphylococcus aureus VISA.jpg
Scanning electron micrograph (SEM) shows a strain of Staphylococcus aureus bacteria taken from a vancomycin intermediate resistant culture (VRSA).
Specialty Microbiology
Diagnostic method Disk diffusion[1]
Treatment Beta-lactam antibiotic (in combination)[2]

Vancomycin-resistant Staphylococcus aureus are strains of Staphylococcus aureus that have become resistant to the glycopeptide antibiotic vancomycin.[3]




Contents






  • 1 Mechanism of acquired resistance


  • 2 Diagnosis


  • 3 Treatment of infection


  • 4 History


    • 4.1 Vancomycin-intermediate S. aureus (VISA)


    • 4.2 Vancomycin-resistant S. aureus (VRSA)


    • 4.3 Heterogeneous vancomycin-intermediate S. aureus (hVISA)




  • 5 See also


  • 6 References


  • 7 Further reading


  • 8 External links





Mechanism of acquired resistance


Strains of hVISA and VISA do not have resistant genes found in Enterococcus and the proposed mechanisms of resistance include the sequential mutations resulting in a thicker cell wall and the synthesis of excess amounts of D-ala-D-ala residues.[4] VRSA strain acquired the vancomycin resistance gene cluster vanA from VRE.[5]



Diagnosis


The diagnosis of vancomycin-resistant Staphylococcus aureus can be done with disk diffusion(and VA screen plate)[1]



Treatment of infection




Rifampicin(Rifampin)


For isolates with a Vancomycin MIC > 2 µg/mL, an alternative to Vancomycin should be used. The approach is to treat with at least one agent to which VISA/VRSA is known to be susceptible by in vitro testing. The agents that are used include daptomycin, linezolid, telavancin, ceftaroline, quinupristin–dalfopristin. For people with MRSA bacteremia in the setting of vancomycin failure the IDSA recommends high-dose daptomycin, if the isolate is susceptible, in combination with another agent (e.g. gentamicin, rifampin, linezolid, TMP-SMX, or a beta-lactam antibiotic).[2]



History


Three classes of vancomycin-resistant S. aureus have emerged that differ in vancomycin susceptibilities: vancomycin-intermediate S. aureus (VISA), heterogeneous vancomycin-intermediate S. aureus (hVISA), and high-level vancomycin-resistant S. aureus (VRSA).[6]



Vancomycin-intermediate S. aureus (VISA)


VISA (/ˈviːsə/ or /viːaɪɛseɪ/) was first identified in Japan in 1996[7] and has since been found in hospitals elsewhere in Asia, as well as in the United Kingdom, France, the U.S., and Brazil. It is also termed GISA (glycopeptide-intermediate Staphylococcus aureus), indicating resistance to all glycopeptide antibiotics. These bacterial strains present a thickening of the cell wall, which is believed to reduce the ability of vancomycin to diffuse into the division septum of the cell required for effective vancomycin treatment.[8]





S. aureus blood agar



Vancomycin-resistant S. aureus (VRSA)


High-level vancomycin resistance in S. aureus has been rarely reported.[9]In vitro and in vivo experiments reported in 1992 demonstrated that vancomycin resistance genes from Enterococcus faecalis could be transferred by gene transfer to S. aureus, conferring high-level vancomycin resistance to S. aureus.[10] Until 2002 such a genetic transfer was not reported for wild S. aureus strains. In 2002, a VRSA strain (/ˈvɜːrsə/ or /viːɑːrɛseɪ/) was isolated from a patient in Michigan.[11] The isolate contained the mecA gene for methicillin resistance. Vancomycin MICs of the VRSA isolate were consistent with the VanA phenotype of Enterococcus species, and the presence of the vanA gene was confirmed by polymerase chain reaction. The DNA sequence of the VRSA vanA gene was identical to that of a vancomycin-resistant strain of Enterococcus faecalis recovered from the same catheter tip. The vanA gene was later found to be encoded within a transposon located on a plasmid carried by the VRSA isolate. This transposon, Tn1546, confers vanA-type vancomycin resistance in enterococci.[12]



Heterogeneous vancomycin-intermediate S. aureus (hVISA)


The definition of hVISA according to Hiramatsu et al. is a strain of Staphylococcus aureus that gives resistance to vancomycin at a frequency of 10−6 colonies or even higher.[13]



See also



  • Antibiotic resistance

  • Drug resistance


  • Methicillin-resistant Staphylococcus aureus (MRSA)(Vancomycin intermediate-resistant Staphylococcus aureus redirect)

  • Vancomycin



References





  1. ^ ab Loomba, Poonam Sood; Taneja, Juhi; Mishra, Bibhabati (2010-01-01). "Methicillin and Vancomycin Resistant S. aureus in Hospitalized Patients". Journal of Global Infectious Diseases. 2 (3): 275–283. doi:10.4103/0974-777X.68535. ISSN 0974-777X. PMC 2946685. PMID 20927290..mw-parser-output cite.citation{font-style:inherit}.mw-parser-output q{quotes:"""""""'""'"}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-limited a,.mw-parser-output .cs1-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}


  2. ^ ab Liu, Catherine; et al. (2011). "Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus Aureus Infections in Adults and Children". Clinical Infectious Diseases. 52: e18–e55. doi:10.1093/cid/ciq146. PMID 21208910.


  3. ^ "CDC - VISA / VRSA in Healthcare Settings - HAI". www.cdc.gov. Retrieved 2015-06-11.


  4. ^ Howden, Benjamin P.; Davies, John K.; Johnson, Paul D. R.; Stinear, Timothy P.; Grayson, M. Lindsay (2010-01-01). "Reduced Vancomycin Susceptibility in Staphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications". Clinical Microbiology Reviews. 23 (1): 99–139. doi:10.1128/CMR.00042-09. ISSN 0893-8512. PMC 2806658. PMID 20065327.


  5. ^ Chang, Soju; Sievert, Dawn M.; Hageman, Jeffrey C.; Boulton, Matthew L.; Tenover, Fred C.; Downes, Frances Pouch; Shah, Sandip; Rudrik, James T.; Pupp, Guy R. (2003-04-03). "Infection with Vancomycin-Resistant Staphylococcus aureus Containing the vanA Resistance Gene". New England Journal of Medicine. 348 (14): 1342–1347. doi:10.1056/NEJMoa025025. ISSN 0028-4793. PMID 12672861.


  6. ^ Appelbaum PC (November 2007). "Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA)". Int. J. Antimicrob. Agents. 30 (5): 398–408. doi:10.1016/j.ijantimicag.2007.07.011. PMID 17888634.


  7. ^ Hiramatsu, K.; Hanaki, H.; Ino, T.; Yabuta, K.; Oguri, T.; Tenover, F. C. (1997-07-01). "Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility". Journal of Antimicrobial Chemotherapy. 40 (1): 135–136. doi:10.1093/jac/40.1.135. ISSN 0305-7453. PMID 9249217.


  8. ^ Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML (Jan 2010). "Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications". Clin. Microbiol. Rev. 23 (1): 99–139. doi:10.1128/CMR.00042-09. PMC 2806658. PMID 20065327.


  9. ^ Gould IM (December 2010). "VRSA-doomsday superbug or damp squib?". Lancet Infect Dis. 10 (12): 816–8. doi:10.1016/S1473-3099(10)70259-0. PMID 21109164.


  10. ^ Proft, Thomas (2013). Bacterial Toxins: Genetics, Cellular Biology and Practical Applications. Horizon Scientific Press. ISBN 9781908230287.


  11. ^ Amábile-Cuevas, Carlos F. (2007). Antimicrobial Resistance in Bacteria. Horizon Scientific Press. ISBN 9781904933243.


  12. ^ Courvalin P (January 2006). "Vancomycin resistance in gram-positive cocci". Clin. Infect. Dis. 42 Suppl 1: S25–34. doi:10.1086/491711. PMID 16323116.


  13. ^ Lu, Yichen; Essex, Max; Roberts, Bryan (2008-04-11). Emerging Infections in Asia. Springer Science & Business Media. ISBN 9780387757216.




Further reading



  • Chang, Soju; Sievert, Dawn M.; Hageman, Jeffrey C.; Boulton, Matthew L.; Tenover, Fred C.; Downes, Frances Pouch; Shah, Sandip; Rudrik, James T.; Pupp, Guy R. (April 3, 2003). "Infection with Vancomycin-Resistant Staphylococcus aureus Containing the vanA Resistance Gene". New England Journal of Medicine. 348 (14): 1342–1347. doi:10.1056/NEJMoa025025. ISSN 0028-4793. PMID 12672861.


External links





Classification
D


  • ICD-9-CM: V09.8

  • PubMed








-

Popular posts from this blog

Guess what letter conforming each word

Image
6 $begingroup$ This is an entry in the Fortnightly Topic Challenge #41: Short and Sweet. 1 letter only could be mean anything . With an additional letter in front , could be used as medicine component and something you definitely learn or at least heard once. Add another letter in front , you would possibly hear that many times . Add an additional letter in front , you would found an independent country . With an additional letter, in the end , you would found something related to apple . Add another letter in the end , you would found something bad . Hint: Each letter is unique . word knowledge letters chemistry share | improve this question ...
Read more

Port of Spain

Image
For ports in the country of Spain, see List of ports in Spain. City in City of Port of Spain, Trinidad and Tobago Port of Spain City City of Port of Spain Top to bottom (left to right): Skyline of Port of Spain from Gulf of Paria; National Academy for the Performing Arts, Independence Square, Eric Williams Plaza; MovieTowne, Port of Port of Spain Motto(s):  "We Gather Strength As We Go Along" Port of Spain Coordinates: 10°40′N 61°31′W  /  10.667°N 61.517°W  / 10.667; -61.517 Coordinates: 10°40′N 61°31′W  /  10.667°N 61.517°W  / 10.667; -61.517 Country   Trinidad and Tobago Jurisdiction City of Port of Spain Settled 1560 Incorporated (town) 1853 Incorporated (city) 1914 Government  • Mayor Joel Martinez  • Governing body City Corporation Area [1]  • City 12 km 2 (5 sq mi) Elevation [2] 66 m (217 ft) Population (2011) [1]  • City 37,074  • Rank 3rd  • Density 3,090/km 2 (8,000/sq mi)...
Read more

Run scheduled task as local user group (not BUILTIN)

Image
0 I am trying to run a scheduled task with User Group (not a single user). This is working fine when I in the field "when running a task, use the following user account:" insert BUILTIN User Group (for example: Administrators or Users). But when I try it with the created Local User Group (example: TestGroup) it is not working. The Users in the TestGroup are the same as in the Administrators group. What could be the problem? Are there some restrictions to the Created User Group compared to BUILTINUsers? scheduled-tasks taskscheduler windowstaskschedule share | improve this question asked Nov 15 '18 at 15:36 Far...
Read more